The impact of glaucomatous optic neuropathy on the daily life of patients is poorly characterized and does not benefit from standardized tests.
The development and validation of new tests could be used to assess the efficacy of innovative treatments for visually impaired patients and/or optimize management strategies.
Age: 18 - 80 years,
Visual acuity of at least 6/10th binocular,
Patient followed at Quinze-Vingts and presenting with chronic stable glaucoma defined by the glaucoma ophthalmologist,
MMSE questionnaire score ≥ 25/30 or ≥ 16/25 (if the patient no longer drives),
Pregnant women.
Inability to personally give consent.
Participants will not have neurodegenerative diseases or any other disease that could interfere with the assessments planned during this study.
Participants will not have any other ophthalmologic diseases other than glaucoma.